Calcipotriol/betamethasone dipropionate: A review of its use in the treatment of psoriasis vulgaris

American Journal of Clinical Dermatology

Volumn 5, Issue 6, 2004, Pages 463-478

  Fenton, Caroline ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CORTICOSTEROID; PLACEBO; TACALCITOL; VIMENTIN; VITAMIN D DERIVATIVE;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DEPIGMENTATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSFORMATION; ECCHYMOSIS; FACE EDEMA; FOLLICULITIS; HUMAN; INFLAMMATION; ISOTOPE LABELING; KERATINOCYTE; LONG TERM CARE; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PURPURA; PUSTULE; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SHORT COURSE THERAPY; SIDE EFFECT; SKIN ABSORPTION; SKIN ATROPHY; SKIN INFLAMMATION; SKIN IRRITATION; SKIN PAPILLOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STRATUM CORNEUM; SYSTEMATIC REVIEW;

BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 13144254253     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405060-00012     Document Type: Review

References (59)

1. Gottlieb AB. Psoriasis. Dis Manage Clin Outcomes 1998 Nov-Dec; 1 (6): 195-202
2. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332 (9): 381-8
3. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatol Treat 2004; 15: 27-9
4. Gawkrodger DJ. On behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists. Current management of psoriasis. J Dermatol Treat 1997 Mar; 8: 27-55
5. Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004 Jan; 135 (1): 1-8
6. Lebwohl M, Ali S. Treatment of psoriasis. Part 1: topical therapy and phototherapy. J Am Acad Dermatol 2001; 45 (4): 487-98
7. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment: a review of its use in the management of psoriasis. Am J Clin Dermatol 2001; 2 (2): 95-120
8. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002 Jan; 46: 1-23
9. Guilhou JJ. The therapeutic effects of vitamin D3 and its analogues in psoriasis. Expert Opin Invest Drugs 1998 Jan; 7 (1): 77-84
10. Bos JD, Krieg SR. Psoriasis infiltrating cell immunophenotype: changes induced by PUVA or corticosteroid treatment in T-cell subsets, Langerhans' cells and interdigitating cells. Acta Derm Venereol (Stockh) 1985; 65: 390-7
11. de Jong EMGJ, Ferrier CM, de Zwart A, et al. Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 1995; 9 (1995): 185-94
12. Reichrath J, Muller SM, Kerber A, et al. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997 Jan; 36 (1): 19-28
13. Jensen AM, Llado MB, Skov L, et al. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998 Dec; 139 (6): 984-91
14. Cagnoni ML, Ghersetich I, Lotti T, et al. Treatment of psoriasis vulgaris with topical calcipotriol: is the clinical improvement of lesional skin related to a down-regulation of some cell adhesion molecules? Acta Derm Venereol Suppl (Stockh) 1994; 186: 55-7
15. Jacob SE, Nassiri M, Kerdel FA, et al. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003 Oct; 12 (5): 309-13
16. Michel G, Gailis A, Jarzebska-Deussen B, et al. 1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997 Jan; 46 (1): 32-4
17. van derVleuten CJM, de Jong EMGJ, van de Kerkhof PCM. Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res 1996; 288: 366-72
18. van Rossum MM, van Erp PEJ, van de Kerkhof PCM. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. Dermatology 2001; 203 (2): 148-52
19. Bernerd F, Magnaldo T, Darmon M. Delayed onset of epidermal differentiation in psoriasis. J Invest Dermatol 1992; 98: 902-10
20. van de Kerkhof PCM. Reduction of epidermal abnormalities and inflammatory changes in psoriatic plaques during treatment with vitamin D3 analogs. J Investig Dermatol Symp Proc 1996 Apr; 1: 78-81
21. Berth-Jones J. The emergence of vitamin D as a first-line treatment for psoriasis. J Dermatol Treat 1998; 9 Suppl. 3: 13-8
22. Candi E, Oddi S, Terrinoni A, et al. Transglutaminase 5 cross-links loricrin, involucrin, and small proline-rich proteins in vitro. J Biol Chem 2001 Sep; 276 (37): 35014-23
23. Vissers WH, Berends M, Muys L, et al. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol 2004 Feb; 13 (2): 106-12
24. Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol 2004; 43 (8): 611-7
25. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985 Jan; 121: 63-7
26. Thaci D, Boehncke W, Diehl S, et al. Individual variations of treatment response with calcipotriol or/and betamethasone [abstract no. P2032]. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: 769
27. Traulsen J, Hughes-Formella BJ. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology 2003; 207 (2): 166-72
28. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004 Jun; 150 (6): 1167-73
29. Kragballe K, Bibby AJ, Jolliffe D. A 52-week safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet®) in the treatment of psoriasis vulgaris [plus poster]. 13th Annual Congress of the European Academy of Dermatology and Venereology; 2004 Nov 17-21; Florence
30. Nissen JB, Avrach WW, Hansen ES, et al. Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment. Dermatology 1999; 198 (1): 11-7
31. Cavicchini S, Brezzi A, Gasparini G, et al. Skin ultrastructure after calcipotriol treatment: a transmission electron microscopic and freeze-fracture study on psoriatic patients. Acta Derm Venereol (Stockh) 1996 May; 76: 186-9
32. Palleschi GM, Gentili A, Caproni M, et al. Structural alterations of basal keratinocytes and capillary loop in psoriasis during treatment with topical calcipotriol. Acta Derm Venereol (Stockh) 1994; (Suppl. 186): 49-51
33. Guzzo C, Lazarus G, Goffe BS, et al. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis. J Am Acad Dermatol 1996 Mar; 34: 429-33
34. Gumowski-Sunek D, Rizzoli R, Saurat JH. Oral calcium tolerance test in extensive psoriasis treated with topical calcipotriol. Dermatology 1995; 190 (1): 43-7
35. Bourke JF, Berth-Jones J, Mumford R, et al. High dose topical calcipotriol consistently reduces serum parathyroid hormone levels. Clin Endocrinol (Oxf) 1994 Sep; 41 (3): 295-7
36. Bourke JF, Mumford R, Whittaker P, et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997 Dec; 37 (6): 929-34
37. Pershing LK, Lambert L, Wright ED, et al. Topical 0.050% betamethasone dipropionate: pharmacokinetic and pharmacodynamic dose-response studies in humans. Arch Dermatol 1994 Jun; 130: 740-7
38. Pershing LK, Corlett JL, Lambert LD, et al. Cirdacian activity of topical 0.05% betamethasone dipropionate in human skin in vivo. J Invest Dermatol 1994 May; 102 (5): 734-9
39. Pershing LK, Silver BS, Krueger GG, et al. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay. Pharm Res 1992 Jan; 9 (1): 45-51
40. Leo Laboratories Limited. Dovobet® ointment: product information 2004 Oct [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Feb 16]
41. Delaney C, Liao W, Cohen M, et al. Percutaneous absorption of calcipotriene (calcipotriol) in normal volunteers and psoriatic patients after a single dose of 3H-calcipotriene and in psoriatic patients after a single dose of 3H-calcipotriene following multiple dose treatment with non-radiolabeled calcipotriene 0.005% ointment [abstract no. 46]. J Investig Dermatol Symp Proc 1996 Apr; 1 (1): 112
42. Yoshikawa K, Nomura M, Higashiyama M, et al. Clinical pharmacological study on MC903 ointment: pharmacokinetic investigation in patients with psoriasis vulgaris (in Japanese). Rinsho Iyaku 1995; 11 (11): 2379-89
43. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205 (4): 389-93
44. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82 (2): 131-5
45. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003 Jan; 48 (1): 48-54
46. Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/ betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004; 209: 308-13
47. Guenther L, Cambazard F, Van de Kerkhof PC, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002 Aug; 147 (2): 316-23
48. van De Kerkhof PCM. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004 Sep; 151 (3): 663-8
49. LEO Pharma. Data on file. 2004 Dec 3
50. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002; 146 (3): 351-64
51. Lea AP, Goa KL, Calcipotriol: a review of its pharmacological properties and therapeutic efficacy in the management of psoriasis. Clin Immunother 1996 Mar; 5 (3): 230-48
52. Kragballe K, Olsen P. Efficacy of once daily application of a new two-compound calcipotriene/betamethasone dipropionate ointment in extensive psoriasis [abstract no. 558]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 144
53. Wasel R, Kragballe K, van de Kerkhof PCM, et al. A new anti-psoriatic ointment yields high efficacy irrespective of initial disease levels [abstract no. P555]. J Am Acad Dermatol 2004; 50 (3 Suppl.): P143 Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 2004 Feb 6-11, Washington DC
54. Wasel R, Kragballe K, van de Kerkhof PCM, et al. A new anti-psoriatic ointment yields high efficacy irrespective of initial disease levels [abstract no. P555]. J Am Acad Dermatol 2004; 50 (3 Suppl.): P143 Plus poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 2004 Feb 6-11, Washington DC
55. Noerregaard J, Lowson D. The cost-utility of calcipotriol/betamethasone (Dovobet) ointment in the treatment of psoriasis vulgaris in the United Kingdom [abstract no. PSN5]. Value Health 2003; 6 (6): 785
56. Sorensen M, Norregaard J. Pharmacoeconomic evaluation of a new two compound ointment (Daivobet®) and calcipotriol (Daivonex®) in the treatment of psoriasis vulgaris in Sweden [abstract no. PES10]. Value Health 2002; 5: 554-5
57. Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003 Apr; 48 (4): 564-8
58. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimes. J Am Acad Dermatol 1997; 37 (3 Pt 2): S55-8
59. Poulin Y. Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis. Skin Therapy Lett 2002 Jun; 7 (6): 1-3